channels war 
Drug Channels
JUNE 27, 2023
Before you launch your July 4 festivities, Drug Channels offers some fireworks of our own: My $0.02 on the Humira price war—and the role of cost-plus pharmacy pricing Fresh evidence that formulary exclusions hurt patients Disturbing oncology drug benefit management Plus, an entertaining explanation of why the U.S.
Drug Channels
APRIL 3, 2024
This week, I’m rerunning some popular posts while I prepare for Friday’s live video webinar: Drug Channel Implications of the Inflation Reduction Act. Unfortunately, the gross-to-net bubble will remain a fixture for this category, despite a price war led by almost half of the biosimilars. All rights reserved.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Channels
JANUARY 9, 2024
Unfortunately, the gross-to-net bubble will remain a fixture for this category, despite a price war led by almost half of the biosimilars. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. This year, Humira and its 13 biosimilars will provide the most intriguing formulary drama.
Drug Channels
JUNE 29, 2022
Through the Drug Channels Institute, I strive to provide you with fact-based and balanced coverage—along with links to source materials so you can make up your own mind. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. This Feed is for personal non-commercial use only.
Drug Channels
JULY 18, 2023
But as I see it, the Humira price war signals that rebate walls will crumble and the gross-to-net bubble will pop. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. These shortcomings, combined with physician hesitancy, will limit the ability of price to drive adoption.
Drug Channels
SEPTEMBER 7, 2022
However, the IRA won’t affect the coming Humira price war. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. Despite these positive recent developments, the just-passed Inflation Reduction Act (IRA) seems likely to disrupt the biosimilar market by altering launch strategies.
Drug Channels
OCTOBER 3, 2023
But as I see it, the Humira price war signals that rebate walls will crumble and the gross-to-net bubble will pop. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. These shortcomings, combined with physician hesitancy, will limit the ability of price to drive adoption.
Expert insights. Personalized for you.
82 
Let's personalize your content